New Approaches to Multiple Myeloma Therapy
The goal of this activity is to increase participants’ competence and performance in applying the best evidence-based, guideline-driven treatment options to optimize the care of patients with multiple myeloma and improve patient outcomes.
This program is designed to meet the educational needs of physicians, physician assistants, nurse practitioners, nurses, pharmacists, and other health care professionals who care for patients with multiple myeloma.
Following this activity, participants should be able to:
- Choose optimal imaging techniques for diagnosis and follow-up of patients with multiple myeloma
- Select appropriate evidence-based strategies for management of patients with newly diagnosed multiple myeloma, taking individual patient characteristics into consideration
- Evaluate clinical data supporting the current treatment options for patients with relapsed/refractory multiple myeloma
Shaji K. Kumar, MD
Mayo Clinic Cancer Center
NCCN Medical Education Disclosure Policy
It is the policy of NCCN that every 12 months, all faculty, moderators, activity planners and all internal planning staff participating in NCCN continuing education activities are expected to disclose any financial relationships with a commercial interest as defined by the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support. In addition, all faculty presentations have been reviewed for adherence to the ACCME’s Standards for Commercial Support (the provider develops activities/educational interventions independent of commercial interests [SCS 1, 2 and 6] by experts on the topics).
Per the ACCME Standards for Commercial Support, individuals who do not disclose relevant financial relationships will be disqualified from involvement in the CE activity as a content developer, planner, or presenter. A complete list of individuals’ relationships with external entities is available upon request.
NCCN continuing education considers financial relationships to create a “conflict of interest” when an individual has both a financial relationship with a commercial interest and the opportunity to affect CE content about the products or services of a commercial interest with which he/she and/or a spouse or partner has a financial relationship.
NCCN continuing education considers “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. NCCN does not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship.
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.
Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling.
The faculty listed below disclose the following relevant financial relationships:
Shaji K. Kumar, MD
Abbvie, Inc.: Grant/Research Support, Scientific Advisor
Amgen Inc: Grant/Research Support
Bristol-Myers Squibb Company: Grant/Research Support
Carsgen: Grant/Research Support
Celgene Corporation: Scientific Advisor
Cellectar Biosciences: Consulting Fees
Genecentrix: Consulting Fees
Genentech, Inc.: Scientific Advisor
Janssen Pharmaceutical Products, LP: Grant/Research Support, Scientific Advisor
Kite Pharma: Grant/Research Support, Scientific Advisor
Medimmune Inc.: Grant/Research Support, Scientific Advisor
Merck & Co., Inc.: Grant/Research Support, Scientific Advisor
Novartis Pharmaceuticals Corporation: Grant/Research Support
Oncoceptides: Consulting Fees
Roche Laboratories, Inc.: Grant/Research Support
sanofi-aventis U.S: Grant/Research Support
Takeda Pharmaceuticals North America, Inc.: Grant/Research Support, Scientific Advisor
Tenebio: Grant/Research Support
NCCN Staff Disclosures
The NCCN Activity Planning staff listed below discloses no relevant financial relationships:
Melissa Esplen; Mark A. Geisler; Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Rose Joyce; Karen Kanefield; Lisa Perfidio, MS; Shannon Ryan, CMP; Kathy Ann Smith, CHCP; Sarah Weinstein
The NCCN Clinical staff listed below discloses no relevant financial relationships:
Rashmi Kumar, PhD
In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
NCCN designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NCCN designates this educational activity for a maximum of 1.25 contact hours.
NCCN designates this knowledge-based continuing education activity for 1.25 contact hours (0.125 CEUs) of continuing education credit. UAN: JA4008196-0000-20-046-L01-P
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.25 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.
- 1.25 AAPA Category 1 CME credit
- 1.25 ACPE contact hours
- 1.25 AMA PRA Category 1 Credit™
- 1.25 ANCC contact hours
- 1.25 Participation
This webinar was presented live one time only on Monday, May 11, 2020, from 9:00 - 10:15 AM EDT (UTC -4).
To complete this activity, users will need:
- A device with an Internet connection and sound playback capability
- One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
- Internet Explorer is no longer supported
- Adobe Reader or other PDF reader software for certificate viewing/printing